Differential signalling mechanisms predisposing primary human skeletal muscle cells to altered proliferation and differentiation: Roles of IGF-I and TNFα

Experimental Cell Research

Volumn 294, Issue 1, 2004, Pages 223-235

  Foulstone, Emily J ^a   Huser, Camille ^a   Crown, Anna L ^a   Holly, Jeff M P ^a   Stewart, Claire E H ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Apoptosis; Differentiation; Proliferation

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; SOMATOMEDIN C; TUMOR NECROSIS FACTOR ALPHA; UO 126;

ADULT; AGED; APOPTOSIS; ARTICLE; CELL COUNT; CELL CULTURE; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERPLASIA; MALE; MUSCLE BIOPSY; MUSCLE CELL; MUSCLE HYPERTROPHY; MYOBLAST; PRIORITY JOURNAL; PROTEIN FUNCTION; RECTUS ABDOMINIS MUSCLE; SIGNAL TRANSDUCTION; SKELETAL MUSCLE;

RECTUS;

EID: 1242339602     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yexcr.2003.10.034     Document Type: Article

References (39)

1. K.C. Calman, Cancer cachexia. Br. J. Hosp. Med. 27 (1982) 28-29. 33-34.
2. Wilmore D.W. Catabolic illness. N. Engl. J. Med. 325:1991;695-702.
3. DeWys W.D., Begg C., Lavin P.T., Band P.R., Bennett J.M., Bertino J.R., Cohen M.H., Douglass H.O., Engstrom P.F., Ezdinli E.Z., Horton J., Johnson G.J., Moertel C.G., Oken M.M., Perlia C., Rosenbaum C., Silverstein M.N., Skeel R.T., Sponzo R.W., Tormey D.C. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am. J. Med. 69:1980;491-497.
4. Florini J.R., Magri K.A., Ewton D.Z., James P.L., Grindstaff K., Rotwein P.S. "Spontaneous" differentiation of skeletal myoblasts is dependent upon autocrine secretion of insulin-like growth factor-II. J. Biol. Chem. 266:1991;15917-15923.
5. Stewart C.E.H., Rotwein P. Growth, differentiation, and survival: multiple physiological functions for insulin-like growth factors. Physiol. Rev. 76:1996;1005-1026.
6. Kaliman P., Vinals F., Testar X., Palacin M., Zorzano A. Phosphatidylinositol 3-kinase inhibitors block differentiation of skeletal muscle cells. J. Biol. Chem. 271:1996;19146-19151.
7. Li Y., Jiang B., Ensign W.Y., Vogt P.K., Han J. Myogenic differentiation requires signalling through both phosphatidylinositol 3-kinase and p38 MAP kinase. Cell. Signal. 12:2000;751-757.
8. Weyman C.M., Wolfman A. Mitogen-activated protein kinase (MEK) activity is required for inhibition of skeletal muscle differentiation by insulin-like growth factor 1 or fibroblast growth factor 2. Endocrinology. 139:1998;1794-1800.
9. Coolican S.A., Samuel D.S., Ewton D.Z., McWade F.J., Florini J.R. The mitogenic and myogenic actions of insulin-like growth factors utilize distinct signalling pathways. J. Biol. Chem. 272:1997;6653-6662.
10. Adi S., Bin-Abbas B., Wu N.-Y., Rosenthal S.M. Early stimulation and late inhibition of extracellular signal-regulated kinase 1/2 phosphorylation by IGF-I: a potential mechanism mediating the switch in IGF-I action on skeletal muscle cell differentiation. Endocrinology. 143:2002;511-516.
11. Florini J.R., Ewton D.Z., McWade F.J. IGF's, muscle growth, and myogenesis. Diabetes Rev. 3:1995;73-92.
12. James P.L., Jones S.B., Busby W.H. Jr., Clemmons D.R., Rotwein P. A highly conserved insulin-like growth factor binding protein (IGFBP-5) is expressed during myoblast differentiation. J. Biol. Chem. 268:1993;22305-223011.
13. McCusker R.H., Clemmons D.R. Role for cyclic adenosine monophosphate in modulating insulin-like growth factor binding protein secretion by muscle cells. J. Cell. Physiol. 174:1998;293-300.
14. Crown A.L., He X.L., Holly J.M.P., Lightman S.L., Stewart C.E.H. Characterisation of the IGF system in a primary adult human skeletal muscle cell model, and comparison of the effects of insulin and IGF-I on protein metabolism. J. Endocrinol. 167:2000;403-415.
15. Foulstone E.J., Savage P.B., Crown A.L., Holly J.M.P., Stewart C.E.H. Role of insulin-like growth factor binding protein-3 (IGFBP-3) in the differentiation of primary human adult skeletal myoblasts. J. Cell. Physiol. 195:2003;70-79.
16. Oliff A., Defeo-Jones D., Boyer M., Martinez D., Kiefer D., Vuocolo G., Wolfe A., Socher S.H. Tumours secreting human TNF/cachetin induce cachexia in mice. Cell. 50:1987;555-563.
17. Grunfeld C., Wilking H., Neese R., Gavin L.A., Moser A.H., Gilli R., Serio M.K., Feingold K.R. Persistence of the hypertriglyceridemic effect of tumour necrosis factor despite development of tachyphylaxis to its anorectic/cachetic effects in rats. Cancer Res. 49:1993;2554-2560.
18. Teng M.N., Park B.H., Keoppen H.K.W., Tracey K.J., Fendly B.M., Schreiber H.P. Long term inhibition of tumour growth by tumour necrosis factor in the absence of cachexia or T-cell immunity. Proc. Natl. Acad. Sci. U. S. A. 88:1991;3535-3539.
19. Meadows K.A., Holly J.M.P., Stewart C.E.H. Tumour necrosis factor α-induced apoptosis is associated with suppression of insulin-like growth factor binding protein-5 secretion in differentiating murine skeletal myoblasts. J. Cell. Physiol. 183:2000;330-337.
20. Foulstone E.J., Meadows K.A., Holly J.M.P., Stewart C.E.H. Insulin-like growth factors (IGF-I and IGF-II) inhibit C2 skeletal myoblast differentiation and enhance TNFα-induced apoptosis. J. Cell. Physiol. 189:2001;207-215.
21. Cooper R.N., Tajbakhsh S., Mouly V., Cossu G., Buckingham M., Butler-Browne G.S. In vivo satellite cell activation via Myf5 and MyoD in regenerating mouse skeletal muscle. J. Cell. Sci. 112:1999;2895-2901.
22. Henry R.R., Ciardaldi T.P., Abrams-Carter L., Mudaliar S., Park K.S., Nikoulina S.E. Glycogen synthase activity is reduced in cultured skeletal muscle cells of non-insulin-dependent diabetes mellitus subjects. J. Clin. Invest. 98:1996;1231-1236.
23. Saghizadeh M., Ong J.M., Garvey W.T., Henry R.R., Kern P.A. The expression of TNF alpha by human muscle. Relationship to insulin resistance. J. Clin. Invest. 97:1996;1111-1116.
24. Khaled M.A., McCutcheon M.J., Reddy S., Pearman P.L., Hunter G.R., Weinsier R.L. Electrical impedance in assessing human body composition: the BIA method. Am. J. Clin. Nutr. 47:1988;789-792.
25. Blau H.M., Webster C. Isolation and characterisation of human muscle cells. Proc. Natl. Acad. Sci. U. S. A. 78:1981;5623-5627.
26. Miller S.C., Ito H., Blau H.M., Torti F.M. Tumour necrosis factor inhibits human myogenesis in vitro. Mol. Cell. Biol. 8:1988;2295-2301.
27. Kalovidouris A.E., Plotkin Z. Synergistic cytotoxic effect of interferon-gamma and tumour necrosis factor-alpha on cultured human muscle cells. J. Rheumatol. 22:1995;1698-1703.
28. Saito Y., Nonaka I. Initiation of satellite replication in bupivacine-induced myonecrosis. Acta Neuropathol. 88:1994;252-257.
29. Halse R., Pearson S.L., McCormack J.G., Yeaman S.J., Taylor R. Effects of tumour necrosis factor-α on insulin action in cultured human muscle cells. Diabetes. 50:2001;1102-1109.
30. Mitchell P.J., Johnson S.E., Hannon K. Insulin-like growth factor I stimulates myoblast expansion and myofiber development in the limb. Dev. Dyn. 223:2002;12-23.
31. Coleman M.E., DeMayo F., Yin K.C., Lee H.M., Geske R., Montgomery C., Schwartz R.J. Myogenic vector expression of insulin-like growth factor I stimulates muscle cell differentiation and myofiber hypertrophy in transgenic mice. J. Biol. Chem. 270:1995;12109-12116.
32. Powell-Braxton L., Hollingshead P., Warburton C., Dowd M., Pitts-Meek S., Dalton D., Gillett N., Stewart T.A. IGF-I is required for normal embryonic growth in mice. Genes Dev. 7:1993;2609-2617.
33. Lemmey A., Maddison P., Breslin A., Cassar P., Hasso N., McCann R., Whellams E., Holly J. Association between insulin-like growth factor status and physical activity levels in rheumatoid arthritis. J. Rheumatol. 28:2001;29-34.
34. Seger R., Krebs E.G. The MAPK signalling cascade. FASEB J. 9:1995;726-735.
35. Weyman C.M., Ramocki M.B., Taparowsky E.J., Wolfman A. Distinct signalling pathways regulate transformation and inhibition of skeletal muscle differentiation by oncogenic Ras. Oncogene. 14:1997;697-704.
36. Cuenda A., Cohen P. Stress-activated protein kinase-2/p38 and a rapamycin sensitive pathway are required for C2C12 myogenesis. J. Biol. Chem. 274:1999;4341-4346.
37. Frame S., Cohen P. GSK-3 takes centre stage more than 20 years after its discovery. Biochem. J. 359:2001;1-16.
38. Sarbassov D.D., Peterson C.A. Insulin receptor substrate-1 and phosphatidylinositol 3-kinase regulate extracellular signal-regulated kinase-dependent and -independent signalling pathways during myogenic differentiation. Mol. Endocrinol. 12:1998;1870-1878.
39. Rommel C., Bodine S.C., Clarke B.A., Rossman R., Nunez L., Stitt T.N., Yancopoulos G.D., Glass D.J. Mediation of IGF-I-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK-3 pathways. Nat. Cell. Biol. 3:2001;1009-1013.